Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure

Mallinckrodt

Status and phase

Withdrawn

Phase 3

Conditions

Hypoxic Respiratory Failure With Pulmonary Hypertension

Treatments

Drug: Placebo

Drug: Inhaled Nitric Oxide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00922532

IK-3001-HRF-301

Details and patient eligibility

About

This Phase 3, Double-blind, Randomized, Placebo controlled, multicenter study is to confirm the efficacy of inhaled nitric oxide for the management of hypoxic respiratory failure associated with pulmonary hypertension in preterm infants.

Study subjects will be administered either inhaled nitric oxide or placebo to determine if there is a change in oxygenation.

Full description

This trial will be a multi-center, double blind, placebo-controlled, randomized clinical trial. All mothers identified with prolonged rupture of membranes and/or oligohydramnios, and all inborn infants < 30 weeks gestational age (GA) at birth will be screened for enrollment. Infants who meet all inclusion and exclusion criteria within the first 48 hours after birth will be randomized to either inhaled NO starting at 20 ppm, or matched placebo, delivered by means of a blinded INOvent® delivery device. Randomization will be stratified by center and treatment will be assigned using an interactive voice or web-based response system (IVRS). All infants will receive up to 14 days of therapy, following a dose reduction schedule. The primary outcome measure will be change in oxygenation at 1 hour after start of therapy. In order to determine the effects of iNO therapy on survival and need for mechanical ventilation, cross-over will not be allowed.

This clinical trial will attempt to demonstrate if pre-term infants may benefit from treatment with nitric oxide for inhalation. A multi-center study is necessary to recruit an appropriate number of subjects, and to reflect the variability of standard practice across the different participating centers. All treatment assignments are blinded in order to minimize the risk of bias in treatment and data collection. In addition, a concurrent placebo group has been chosen as the most appropriate control group since there may be temporal, institutional and national variations in average outcomes. Methemoglobin levels will be measured locally and will collected in a blinded manner.

Sex

All

Ages

Under 48 hours old

Volunteers

No Healthy Volunteers

Inclusion criteria

Preterm infants who:

Are in-born at < 30 weeks gestational age
Weigh 500-1250 grams
Have hypoxic respiratory failure requiring mechanical ventilation with FiO2 > 0.8 to maintain SaO2 ≥ 85% in the first 48 hours after birth after use of exogenous surfactant
Have minimal parenchymal lung disease by chest X ray

Exclusion criteria

Preterm infants who:

Have ten minute Apgar score < 5
Have life-threatening anomalies (cardiac, thoracic, chromosomal) or congenital diaphragmatic hernia with lung hypoplasia, or any child who will not receive complete intensive care
Have bilateral Grade IV Intraventricular Hemorrhage (IVH)
Are dependent on right to left shunting to maintain the systemic circulation
Have received prior iNO therapy
Have had treatment with investigational medications